What are the resources available to help patients connect with others living with similar conditions?

A specific anti-complement treatment (eculizumab; its brand name is Soliris) ... If eculizumab is started, how long does it need to be continued? When a ... Eculizumab blocks the complement pathway. ▫ Humanised version of anti-C5 antibody, binding specifically to the complement protein. C5 (NHS 2012). 600mg weekly for the first 4 weeks, followed by 900mg for the fifth dose 1 week later, then 900mg every 2 weeks thereafter. Aug 24, 2023 ... Pioneering treatment highly effective for rare kidney disease ... A pioneering drug for a rare kidney disease prevents organ failure and ... Apr 10, 2019 ... Eculizumab (Soliris®, Alexion Pharmaceuticals, Inc., Boston, MA, USA) ... Soliris (eculizumab) [prescribing information]. Boston, MA ... Soliris is not expected to affect the aplastic component of anaemia in patients with PNH. Meningococcal Infection. Due to its mechanism of action, the use of ... Nov 25, 2008 ... Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2008;142(2): ... eculizumab ... A drug used to prevent red blood cells from being destroyed in patients with a rare red blood cell disorder called paroxysmal nocturnal ... Jul 22, 2024 ... FDA Approves Epysqli as Second Soliris Biosimilar ... The FDA approves Samsung Bioepis' Epysqli (eculizumab-aagh), marking the second US approval ... NMOSD patients receiving Soliris should be monitored for early signs of meningococcal infection. No ongoing monitoring is recommended following discontinuation ...